Showing results (2501-2510 of 2,674) with videos related to

Sort By:
Pageof 268
Clinical Genitourinary Cancer|June 23, 2026
Pembrolizumab and Denosumab in Clear-Cell Renal-Cell CarcinomaCarole A Harris, Danka S Zebic, Michelle F Morris, et al.
BJU International|July 17, 2021
'Pain-free TRUS B': a phase 3 double-blind placebo-controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonography-guided prostate biopsy (ANZUP 1501)Dickon Hayne, Jeremy Grummet, David Espinoza, et al.
The Journal of Pediatrics|February 8, 2025
Overlapping Clinical Phenotypes in Patients with Primary Ciliary Dyskinesia or Activated Phosphoinositide 3-Kinase Delta SyndromeAdam J Shapiro, Eveline Y Wu, Deborah J Morris-Rosendahl, et al.
BJU International|November 21, 2023
A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinomaCiara Conduit, Ian D Davis, Jeffrey C Goh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2005
Phase I trial of 131I-huA33 in patients with advanced colorectal carcinomaGeoffrey Chong, Fook Thean Lee, Wendie Hopkins, et al.
The Lancet. Oncology|August 2, 2025
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trialLouise Emmett, Nathan Papa, Shalini Subramaniam, et al.
European Urology Oncology|February 11, 2020
Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumFrede Donskov, Wanling Xie, Anders Overby, et al.
European Urology|October 29, 2015
Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 StudiesJoaquim Bellmunt, Thian Kheoh, Margaret K Yu, et al.
Nature|January 11, 2019
A recurrent nova super-remnant in the Andromeda galaxyM J Darnley, R Hounsell, T J O'Brien, et al.
Nature Cancer|April 15, 2026
Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trialLouise Emmett, Mina Swiha, Nathan Papa, et al.
Pageof 268